PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19147568-5	2009	Here, we report that DFMO treatment, but not Odc heterozygosity, impairs MYCN-induced neuroblastoma and that, in this malignancy, transient DFMO treatment is sufficient to confer protection.	Eflornithine	21-25	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	73-77	
19147568-6	2009	The selective anticancer effects of DFMO on mouse and human MYCN-amplified neuroblastoma also rely on its ability to disable the proliferative response of Myc, yet in this tumor context, DFMO targets the expression of the p21(Cip1) Cdk inhibitor, which is also suppressed by Myc oncoproteins.	Eflornithine	36-40	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	60-64	
19147568-6	2009	The selective anticancer effects of DFMO on mouse and human MYCN-amplified neuroblastoma also rely on its ability to disable the proliferative response of Myc, yet in this tumor context, DFMO targets the expression of the p21(Cip1) Cdk inhibitor, which is also suppressed by Myc oncoproteins.	Eflornithine	187-191	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	60-64	
19147568-7	2009	These findings suggest that agents, such as DFMO, that target the polyamine pathway may show efficacy in high-risk, MYCN-amplified neuroblastoma.	Eflornithine	44-48	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	116-120